Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies

17 Sept 2021

Abstract excerpt

Abstract Antibody engineering technologies face increasing demands for speed, reliability and scale. We develop CeVICA, a cell-free nanobody engineering platform that uses ribosome display for in vitro selection of nanobodies from a library of 10 11 randomized sequences. We apply CeVICA to engineer nanobodies against the Receptor Binding Domain (RBD) of SARS-CoV-2 spike protein and identify >800 binder families...

Topics

Join the communities discussing this publication.

Monoclonal and Polyclonal Antibodies Research
SARS-CoV-2 and COVID-19 Research
vaccines and immunoinformatics approaches

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34535642
DOI: 10.1038/s41467-021-25777-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodiesPMID 34535642Read ↗

Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2Semantic proximity Read ↗

Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2Semantic proximity Read ↗

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.Semantic proximity Read ↗

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2Semantic proximity Read ↗

Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape.Semantic proximity Read ↗

Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escapeSemantic proximity Read ↗

Expanding and improving nanobody repertoires using a yeast display method: Targeting SARS-CoV-2Semantic proximity Read ↗

Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learningSemantic proximity Read ↗

Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity NanobodySemantic proximity Read ↗

Design of nanobody targeting SARS-CoV-2 spike glycoprotein using CDR-grafting assisted by molecular simulation and machine learningSemantic proximity Read ↗

Versatile, Multivalent Nanobody Cocktails Efficiently Neutralize SARS-CoV-2Semantic proximity Read ↗

Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.